Novavax Inc (NVAX)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

21 FIRSTFIELD ROAD GAITHERSBURG, MD 20878

Novavax is a clinical-stage biopharmaceutical company focused on developing recombinant vaccines to address a range of infectious diseases. Co.'s technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles and recombinant nanoparticle vaccines. Co.'s product pipeline targets a range of infectious diseases and its vaccine candidates are in or have completed clinical trials that target pandemic influenza, seasonal influenza and respiratory syncytial virus. Further, CPL Biologics Private Limited, Co.'s joint venture company in India, is developing a rabies vaccine candidate.

Data as of 2020-11-22
Market Cap5.51 Billion Shares Outstanding63.66 Million Avg 30-day Volume3.271 Million
P/E Ratio-16.7 Dividend Yield EPS-5.17
Price/Sales26.909 Price cash flow ratio66.9 Price free cash flow ratio-48.0
Book Value1.67 Price to Tangible Book-213.36 Alpha0.04
Short Interest Ratio % Short Interest to Float R-squared0.031456
BETA1.62106 52-week High/Low189.4 / 3.6518 Stddev0.385163
View SEC Filings from NVAX instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 6 1 500.0% 6 (0.39%) 3 (0.19%) 100.0%
Funds Holding: 301 209 44.02% 76 (5.0%) 43 (2.79%) 76.74%
13F shares: 31.754 Million 31.766 Million -0.04% 8.511 Million 10.627 Million -19.91%
% Ownership 51.82 54.1277 -4.26% 13.8883 18.107 -23.3%
New Positions: 119 116 2.59% 39 31 25.81%
Increased Positions 89 53 67.92% 12 9 33.33%
Closed Positions 24 20 20.0% 7 4 75.0%
Reduced Positions 76 27 181.48% 23 3 666.67%
Total Calls 4.124 Million 2.629 Million 56.89% 1.124 Million 333.1 Thousand 237.35%
Total Puts 4.878 Million 3.341 Million 46.0% 1.841 Million 506.707 Thousand 263.37%
PUT/CALL Ratio 1.18 1.27 -7.09% 1.64 1.52 7.89%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding NVAX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NVAX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

52.3 Thousand total shares from 6 transactions

Exercise Derivative Conversion (M)

52.3 Thousand total shares from 2 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

ERCK STANLEY C PRESIDENT AND CEO

  • Officer
  • Director
20,495 2020-11-16 7

COVINO GREGORY F EVP, CHIEF FINANCIAL OFFICER

  • Officer
0 2020-11-16 2

ALTON GREGG H

  • Director
0 2020-10-31 2

TRIZZINO JOHN EVP, CBO AND CFO

  • Officer
5,087 2020-09-30 8

GLENN GREGORY M PRESIDENT, R&D

  • Officer
1,561 2020-09-28 8

HERRMANN JOHN A III EVP, CHIEF LEGAL OFFICER

  • Officer
275 2020-09-28 8

EVANS GARY C

  • Director
16,724 2020-08-18 4

MCMANUS MICHAEL A JR

  • Director
9,951 2020-08-18 3

DOUGLAS RICHARD

  • Director
0 2020-06-25 2

YOUNG JAMES F

  • Director
0 2020-06-25 4

KING RACHEL K.

  • Director
0 2020-06-25 2

MOTT DAVID M

  • Director
0 2020-06-25 3

PHILLIPS BARCLAY A SVP, CHIEF FINANCIAL OFFICER

  • Officer
38,669 2017-07-31 0

BOUDREAUX GAIL

  • Director
0 2017-03-16 0

MODI RAJIV I.

  • Director
2,500,000 2015-06-16 0

WILSON RUSSELL P SVP, BUSINESS DEVELOPMENT

  • Officer
0 2015-03-05 0

HAHN TIMOTHY JON SVP, MANUFACTURING

  • Officer
0 2015-03-05 0

CADILA PHARMACEUTICALS LTD

SATELLITE OVERSEAS (HOLDINGS) LTD

  • 10% Owner
No longer subject to file 2014-03-12 0

MARSH JOHN O JR

  • Director
0 2014-03-06 0

DRISCOLL FREDERICK W VP, CFO & TREASURER

  • Officer
0 2013-03-02 0

SINGHVI RAHUL PRESIDENT, CEO

  • Officer
  • Director
0 2011-03-10 0

THORNTON MARK OWENS SVP & CHIEF MEDICAL OFFICER

  • Officer
25,000 2010-05-24 0

LAMBERT JOHN A

  • Director
0 2010-04-15 0

JOHNSTON THOMAS SCOTT VICE PRESIDENT, STRATEGY

  • Officer
0 2010-03-15 0

HEATON PENNY VP & CHIEF MEDICAL OFFICER

  • Officer
18,667 2009-07-02 0

HAGE RAYMOND JOSEPH SR. VP. COMMERCIAL OPERATIONS

  • Officer
11,512 2009-07-01 0

KOPSIDAS EVDOXIA E SR.DIR.FIN.,PRIN.ACCTG.OFFICER

  • Officer
0 2009-06-17 0

ROBINSON JIM VP, TECHNICAL & QUALITY OPS.

  • Officer
0 2009-03-05 0

MONATH THOMAS P

  • Director
0 2009-03-05 0

TANANBAUM JAMES B

  • Director
0 2009-03-05 0

STIGLIANO LEN F VP, CFO, TREASURER

  • Officer
20,554 2008-07-31 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

COVINO GREGORY F - Officer EVP, CHIEF FINANCIAL OFFICER

2020-11-18 18:06:33 -0500 2020-11-16 A 7,300 a 7,300 direct

ERCK STANLEY C - Director - Officer PRESIDENT AND CEO

2020-11-18 18:09:51 -0500 2020-11-16 S 4,909 $93.56 d 20,495 direct yes 0.1736 45.4745 45.4745 6 0.0 1

ERCK STANLEY C - Director - Officer PRESIDENT AND CEO

2020-11-18 18:09:51 -0500 2020-11-16 S 11,234 $89.26 d 47,505 direct yes 0.1736 45.4745 45.4745 6 0.0 1

ERCK STANLEY C - Director - Officer PRESIDENT AND CEO

2020-11-18 18:09:51 -0500 2020-11-16 M 9,818 $25.60 a 72,811 direct 0.1736 45.4745 45.4745 6 0.0 1

ERCK STANLEY C - Director - Officer PRESIDENT AND CEO

2020-11-18 18:09:51 -0500 2020-11-16 M 9,818 d 35,182 direct yes

ERCK STANLEY C - Director - Officer PRESIDENT AND CEO

2020-11-18 18:09:51 -0500 2020-11-16 S 17,503 $92.97 d 25,404 direct yes 0.1736 45.4745 45.4745 6 0.0 1

ERCK STANLEY C - Director - Officer PRESIDENT AND CEO

2020-11-18 18:09:51 -0500 2020-11-16 S 8,306 $88.36 d 58,739 direct yes 0.1736 45.4745 45.4745 6 0.0 1

ERCK STANLEY C - Director - Officer PRESIDENT AND CEO

2020-11-18 18:09:51 -0500 2020-11-16 M 42,499 $39.80 a 62,993 direct 0.1736 45.4745 45.4745 6 0.0 1

COVINO GREGORY F - Officer EVP, CHIEF FINANCIAL OFFICER

2020-11-18 18:06:33 -0500 2020-11-16 A 8,200 a 8,200 direct

ERCK STANLEY C - Director - Officer PRESIDENT AND CEO

2020-11-18 18:09:51 -0500 2020-11-16 M 42,499 d 0 direct yes

ERCK STANLEY C - Director - Officer PRESIDENT AND CEO

2020-11-18 18:09:51 -0500 2020-11-16 S 4,598 $90.61 d 42,907 direct yes 0.1736 45.4745 45.4745 6 0.0 1

ERCK STANLEY C - Director - Officer PRESIDENT AND CEO

2020-11-18 18:09:51 -0500 2020-11-16 S 5,766 $87.20 d 67,045 direct yes 0.1736 45.4745 45.4745 6 0.0 1

ALTON GREGG H - Director

2020-11-03 18:15:49 -0500 2020-10-31 A 7,700 a 7,700 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments